A global perspective on stepping down chronic spontaneous urticaria treatment: Results of the Urticaria Centers of Reference and Excellence SDown-CSU study.

Authors:
Türk M; Kocatürk E; Ertaş R; Ensina LF; Mariel Ferrucci S and 5 more

Journal:
Clin Transl Allergy

Publication Year: 2024

DOI:
10.1002/clt2.12343

PMCID:
PMC10865765

PMID:
38353300

Journal Information

Journal Title: Clin Transl Allergy

Detailed journal information not available.

Publication Details

Subject Category: Allergy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICT OF INTEREST STATEMENT Murat Türk is or recently was a speaker and/or advisor for AstraZeneca, GSK, Novartis, Roxall, Vem İlaç. Emek Kocatürk is or recently was a speaker and advisor for Novartis, Menarini, LaRoche Posey, Sanofi, Bayer, Abdi İbrahim, Pfizer. Ragıp Ertaş is or recently was a speaker and/or advisor for Novartis, Abbvie, Jannsen, and Pfizer. Luis Felipe Ensina is or recently was a speaker and/or advisor for and/or has received research funding from Abbvie, Novartis and Sanofi. Silvia Mariel Ferrucci is or recently was a speaker and/or advisor for and/or has received research funding from ABBVIE, Almirall, Galderma, Leo Pharma, Sanof, Amgen, Novartis, Bayer, Novartis and Menarini. Clive Grattan has sat on Advisory Boards for Celltrion and Blueprint Medicines. He is on Steering Committees for Blueprint Medicines and AB Science. Christian Vestergaard is or recently was a speaker and advisor for Novartis, Sanfoi Genzyme, Ely Lilly, Pfizer, Almirall, LEO Pharma, Astra Zeneca, Pierre Fabre, OM Pharma, and Abbvie. Torsten Zuberbier has received industry consulting, research grants, and/or honoraria from AImmune, AjantaPharma, Astra Zeneca, AbbVie, ALK, Almirall, Astellas, Bayer Health Care, Bencard, Berlin Chemie, BioCryst, Celldex, FAES, HAL, Henkel, Kryolan, Leti, Lofarma, L’Oreal, Meda, MediWound, Menarini, Merck, MMV Medicines for Malaria Venture, MSD, Novartis, PCM Scientific, Pfizer, Sanofi, Sanoflore, Stallergenes, Takeda, Teva, and UCB; and has organizational affiliations with WHO‐Initiative “Allergic Rhinitis and its Impact on Asthma” (ARIA) (committee member), German Society for Allergy and Clinical Immunology (DGAKI) (member of the board), European Centre for Allergy Research Foundation (ECARF) (chairman of the board), Global Allergy and Asthma European Network (GA2LEN) (president), and Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organisation (WAO) (member). Marcus Maurer is or recently was a speaker and/or advisor for and/or has received research funding from Allakos, Alvotech, Amgen, Aquestive, Aralez, AstraZeneca, Bayer, Celldex, Celltrion, Evommune, GSK, Ipsen, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Mitsubishi Tanabe Pharma, Moxie, Noucor, Novartis, Orion Biotechnology, Resoncance Medicine, Sanofi/Regeneron, Septerna, Trial Form Support International AB, Third HarmonicBio, ValenzaBio, Yuhan Corporation, Zurabio. Ana Maria Giménez‐Arnau is or recently was a speaker and/or advisor for and/or has received research funding from Almirall, Amgen, AstraZeneca, Avene, Celldex, Escient Pharmaceuticals, Genentech, GSK, Instituto Carlos III‐ FEDER, Leo Pharma, Menarini, Novartis, Sanofi–Regeneron, Servier, Thermo Fisher Scientific, Uriach Pharma/Neucor."

Evidence found in paper:

"Open Access funding enabled and organized by Projekt DEAL."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025